CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 16 enrolled
Drug / intervention
LY2409021drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02217618
NCT02217618Phase 1Completed
CompareCT.gov

A Single Dose Pharmacokinetic Study of LY2409021 Tablet Administered in Healthy Subjects

Eli Lilly and Company·interventional·Posted Aug 15, 2014·Updated Oct 29, 2018

In Brief

A Phase 1 clinical trial evaluating LY2409021 for Healthy Participants. Completed, enrolled 16 participants across 1 site.

Detailed Summary

The study involves a single dose of LY2409021 taken by mouth. The purpose of this study is to determine how much LY2409021 enters the bloodstream and how long the body takes to get rid of the drug after the dose. This study will last approximately 28 days, not including screening. Screening can occur within 30 days prior to the start of the study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Participants
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedAug 15, 2014
Enrollment StartAug 1, 2014
Primary CompletionSep 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 11.9 years ago

Interventions

LY2409021drug